Abstract: The present invention relates to stable oral compositions of one or more benzimidazole compounds and processes for their preparation. Also provided are methods for treating various gastrointestinal disorders.

Abstract: The present invention relates to stable oral compositions of one or more benzimidazole compounds and processes for their preparation. Also provided are methods for treating various gastrointestinal disorders.

Abstract: The present invention relates to stable oral compositions of one or more benzimidazole compounds and processes for their preparation. Also provided are methods for treating various gastrointestinal disorders.

Abstract: The present invention relates to stable oral compositions of one or more benzimidazole compounds and processes for their preparation. Also provided are methods for treating various gastrointestinal disorders.

Abstract: The present invention relates to pharmaceutical compositions comprising amlodipine and pharmaceutically acceptable salts thereof, and atorvastatin and pharmaceutically acceptable salts thereof, and processes for their preparation.

Abstract: The present invention relates to processes for the preparation of stable oral compositions of benzimidazole compounds prepared using a non-aqueous layering process.

Abstract: The technical field of the invention relates to stable solid dosage forms of amlodipine besylate and benazepril hydrochloride; and processes for their preparation. In particular, the solid dosage forms having reduced levels of 3-ethyl methyl [(2-aminoethoxy)methyl](2-chlorophenyl)methylpyridine-3,5 dicarboxylate (“impurity D”) and total impurities when free of dicalcium phosphate.

Abstract: The present invention relates to solid oral dosage forms of ziprasidone and salts thereof and processes for their preparation, containing colloidal silicon dioxide.

Abstract: The present invention relates to a method for the preparation of bioavailable dosage form of modafinil.

Abstract: The present invention relates to a process for the preparation of solid dosage forms of amorphous valganciclovir hydrochloride by dry method.

Abstract: A pharmaceutical composition includes erythromycin A or a derivative thereof and alginic acid. The alginic acid provides taste masking of the erythromycin A or derivative. The erythromycin A derivative may be clarithromycin and the alginic acid may be one or both of alginic acid and its salt. The salt may be one or more of sodium alginate and calcium alginate. The pharmaceutical composition may further include one or more of a binder, a disintegrant, a flavoring agent, and a coating. The pharmaceutical composition also may include one or more active ingredients, including omeprazole, metronidazole, amoxicillin, rifampicin, lansoprazole, ciprofloxacin, ethambutol, and ritonavir. The erythromycin A or a derivative thereof and the one or more active ingredients may be combined in a single pharmaceutical composition.

Abstract: The invention relates to processes for preparing, and pharmaceutical compositions of, modafinil dosage forms for oral administration. The dosage forms include a mixture of coarse and fine particles of modafinil. The process for preparing modafinil oral dosage forms includes forming a dosage form that includes about 7%–25% by weight of modafinil particles having diameters greater than 220 ?m and about 75%–93% by weight of modafinil particles having diameters less than 220 ?m.

Abstract: The technical field of the invention relates to spray dried, co-precipitate amorphous losartan dosage forms that are stable over time and processes for their preparation. The processes stabilize the amorphous losartan. The process includes preparing an aqueous solution of losartan and one or more hydrophilic polymers; and spray drying the aqueous solution of losartan and one or more hydrophilic polymers to form a mixture. The amorphous losartan and one or more hydrophilic polymers are co-precipitated from the aqueous solution.

Abstract: The present invention generally relates to controlled release dosage forms which provide immediate release and sustained release of nitrofurantoin, and processes for their preparation. The controlled release dosage form includes a sustained release portion and an immediate release portion. The sustained release portion includes nitrofurantoin and one or more pH dependent hydrophilic polymers. The immediate release portion includes nitrofurantoin.

Abstract: The invention provides stable pharmaceutical compositions comprising ACE inhibitor(s) and other pharmaceutically active substances which are susceptible to degradation, as well as processes for the preparation thereof, and methods of treatment involving administration of such compositions.

Abstract: The invention relates to processes for preparing, and pharmaceutical compositions of, modafinil dosage forms for oral administration. The dosage forms include a mixture of coarse and fine particles of modafinil. The process for preparing modafinil oral dosage forms includes forming a dosage form that includes about 7%-25% by weight of modafinil particles having diameters greater than 220 &mgr;m and about 75%-93% by weight of modafinil particles having diameters less than 220 &mgr;m.

Abstract: The present invention relates to a stable pharmaceutical composition comprising pravastatin or its pharmaceutically acceptable salts and a carrier, which imparts a pH between 6.5 and 8.5 to an aqueous dispersion of said composition. The invention also relates to a process for making the pharmaceutical composition.

Abstract: A pharmaceutical composition in the form of a tablet or a capsule for the controlled release of diltiazem, comprises about 30 to about 97% by weight of a hydrophilic polymer, about 0.5 to about 30% by weight of an enteric (pH-dependent) polymer, and about 2.5 to about 60% by weight of diltiazem or a pharmaceutically acceptable salt or ester thereof. The ratio of hydrophilic polymer to enteric polymer is in the range of about 1:1 to about 15:1. Such a pharmaceutical composition releases diltiazem at a rate that allows effective plasma levels of diltiazem to be maintained over a period of twenty-four hours after administration to human adult subjects.